Skip to main content

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

NIH hosts Congressional visitors, May 17, 2021

A group of U.S. Senators visited the Bethesda campus of the National Institutes of Health on May 17, 2021, to learn more about NIH’s response to COVID-19. Part of the NIH tour was a demonstration of diagnostic technologies developed by the NIBIB-led RADx Tech and ATP programs. These programs are part of the NIH RADx Initiative. The Senators viewed at-home, point-of-care, and laboratory tests and testing products. With support from the RADx programs, many of these technologies are now on the market.

NIBIB Director Bruce Tromberg, left, and Senator Roy Blunt (Missouri). (NIH photo by Chia-Chi Charlie Chang)
NIBIB Director Bruce Tromberg, left, and Senator Roy Blunt (Missouri). (NIH photo by Chia-Chi Charlie Chang)
Senators and their staff view an array of 32 COVID-19 testing technologies developed with support from the RADx Tech/ATP program at NIH. (NIBIB photo)
Senators and their staff view an array of 32 COVID-19 testing technologies developed with support from the RADx Tech/ATP program at NIH. (NIBIB photo)
NIH Director Francis Collins welcomes Congressional contingent. (NIBIB photo)
NIH Director Francis Collins welcomes Congressional contingent. (NIBIB photo)
NIBIB Director Bruce Tromberg provides an update on the RADx Tech/ATP program. (NIBIB photo)
NIBIB Director Bruce Tromberg provides an update on the RADx Tech/ATP program. (NIBIB photo)
NIBIB Director Bruce Tromberg demonstrates Ellume COVID-19 antigen test developed with support from NIH RADx Tech/ATP. (NIH photo by Chia-Chi Charlie Chang)
NIBIB Director Bruce Tromberg demonstrates Ellume COVID-19 antigen test developed with support from NIH RADx Tech/ATP. (NIH photo by Chia-Chi Charlie Chang)
From left, Senators Roger Marshall (Kansas), Roy Blunt, (Missouri), and John Boozman (Arkansas) take a closer look at a component of the Mesa Biotech Accula System, a visually read test using RT-PCR technology to detect SARS-CoV-2 at the point of care that provides lab-quality results in about 30 minutes. (NIH photo by Chia-Chi Charlie Chang)
From left, Senators Roger Marshall (Kansas), Roy Blunt, (Missouri), and John Boozman (Arkansas) take a closer look at a component of the Mesa Biotech Accula System, a visually read test using RT-PCR technology to detect SARS-CoV-2 at the point of care that provides lab-quality results in about 30 minutes. (NIH photo by Chia-Chi Charlie Chang)
Senator Roger Marshall (Kansas) poses a question to NIBIB Director Bruce Tromberg during the presentation Q&A. (NIH photo by Chia-Chi Charlie Chang)
Senator Roger Marshall (Kansas) poses a question to NIBIB Director Bruce Tromberg during the presentation Q&A. (NIH photo by Chia-Chi Charlie Chang)
From left, Senators Tammy Baldwin (Wisconsin), John Cornyn (Texas), Chris Van Hollen (Maryland), Lisa Murkowski (Alaska), Roger Marshall (Kansas), Roy Blunt, (Missouri), and John Boozman (Arkansas) discuss diagnostics tech with NIBIB Director Bruce Tromberg. (NIH photo by Chia-Chi Charlie Chang)
From left, Senators Tammy Baldwin (Wisconsin), John Cornyn (Texas), Chris Van Hollen (Maryland), Lisa Murkowski (Alaska), Roger Marshall (Kansas), Roy Blunt, (Missouri), and John Boozman (Arkansas) discuss diagnostics tech with NIBIB Director Bruce Tromberg. (NIH photo by Chia-Chi Charlie Chang)
NIBIB Director Bruce Tromberg, who leads the RADx Tech/ATP program at NIH, responds to a question posed by Senator Tammy Baldwin (Wisconsin). (NIBIB photo)
NIBIB Director Bruce Tromberg, who leads the RADx Tech/ATP program at NIH, responds to a question posed by Senator Tammy Baldwin (Wisconsin). (NIBIB photo)
NIBIB Director Bruce Tromberg demonstrates the Ellume COVID-19 antigen test developed with support from NIH RADx Tech/ATP. (NIBIB photo)
NIBIB Director Bruce Tromberg demonstrates the Ellume COVID-19 antigen test developed with support from NIH RADx Tech/ATP. (NIBIB photo)